NOV 17, 202656 MINS READ
The microbial biosynthesis of L-Methionine proceeds through a highly conserved pathway originating from L-aspartate, involving sequential enzymatic transformations that incorporate reduced sulfur into the amino acid backbone 1,6. The pathway can be conceptually divided into three major modules: (1) aspartate-derived homoserine synthesis, (2) homoserine activation and sulfur incorporation, and (3) homocysteine methylation to yield L-Methionine.
The initial phase begins with L-aspartate phosphorylation by aspartokinase, followed by reduction to L-aspartate-4-semialdehyde and subsequent conversion to L-homoserine through homoserine dehydrogenase 7,8. This carbon skeleton assembly requires 1 ATP and 2 NADPH molecules per L-Methionine synthesized 6,15. In Corynebacterium glutamicum, the thrBC gene cluster encodes bifunctional aspartokinase/homoserine dehydrogenase, representing a key regulatory point subject to feedback inhibition by L-threonine and L-Methionine 14.
L-Homoserine must be activated before sulfur incorporation, achieved through O-acylation to form either O-acetyl-L-homoserine or O-succinyl-L-homoserine 1,12. The enzyme L-homoserine O-acetyltransferase (MetA, EC 2.3.1.31) catalyzes acetyl-CoA-dependent acetylation, while O-succinyl-L-homoserine is generated via MetA homologs utilizing succinyl-CoA 2,13. The choice of acyl donor has significant implications for downstream processing: O-acetyl-L-homoserine pathways generate equimolar acetate as a by-product during sulfhydrylation, which can inhibit microbial growth at concentrations exceeding 20-30 g/L due to cytoplasmic acidification 12. In industrial fermentation systems, this acetate accumulation necessitates either in situ consumption strategies or costly downstream removal processes 12,13.
An alternative activation mechanism involves O-phosphorylation to yield O-phospho-L-homoserine (OPHS), catalyzed by threonine synthase operating in reverse or dedicated phosphorylating enzymes 2. The OPHS-dependent pathway offers thermodynamic advantages, as the sulfhydrylation reaction releases inorganic phosphate rather than organic acids:
O-phospho-L-homoserine + CH₃SH → L-Methionine + H₃PO₄ 2
This route eliminates acetate/succinate by-product formation, significantly improving process economics and reducing downstream purification complexity 2. Mutated cystathionine γ-synthase variants (MetZ) from various bacterial sources exhibit OPHS-dependent methionine synthase activity with kcat values ranging from 0.8 to 3.5 s⁻¹ and KM for OPHS between 0.5-2.0 mM 2,3.
Two fundamentally distinct strategies exist for introducing sulfur into the methionine carbon skeleton, each with unique enzymatic requirements, metabolic costs, and industrial applicability.
Direct sulfhydrylation involves the enzyme-catalyzed condensation of activated homoserine with reduced sulfur compounds, primarily methanethiol (CH₃SH) or hydrogen sulfide (H₂S) 1,3,6. O-Acetyl-L-homoserine sulfhydrylase (MetY/MetZ, EC 2.5.1.49) catalyzes the reaction:
O-acetyl-L-homoserine + CH₃SH → L-Methionine + acetate 12,13
This pathway is energetically favorable, requiring only the ATP/NADPH invested in homoserine synthesis (1 ATP + 2 NADPH) without additional energy expenditure for sulfur reduction 6,15. However, the high toxicity of methanethiol to methionine-producing microorganisms (IC₅₀ typically 0.5-2.0 mM for Corynebacterium and Escherichia species) limits intracellular application 3,6. Industrial implementations employ two-stage processes: fermentative production of O-acyl-homoserine precursors followed by ex vivo enzymatic sulfhydrylation in bioreactors with controlled methanethiol addition 1,12,13.
Engineered MetY/MetZ variants with enhanced substrate affinity and reduced product inhibition have been developed through directed evolution. For example, Corynebacterium humireducens MetZ mutants exhibit 2.5-fold increased kcat/KM for O-acetyl-L-homoserine and 40% reduced acetate inhibition at concentrations above 50 g/L 13.
The transsulfuration route utilizes L-cysteine as the sulfur donor, proceeding through cystathionine intermediates 2,7,8. Cystathionine γ-synthase (MetB, EC 2.5.1.48) condenses O-succinyl-L-homoserine or O-acetyl-L-homoserine with L-cysteine to form L-cystathionine:
O-succinyl-L-homoserine + L-cysteine → L-cystathionine + succinate 7,9
Subsequently, cystathionine β-lyase (MetC/AecD, EC 4.4.1.8) cleaves cystathionine to yield L-homocysteine, ammonia, and pyruvate 10,14. This pathway is prevalent in wild-type Corynebacterium and Escherichia strains but suffers from significant drawbacks for industrial L-Methionine production: (1) cysteine requirement increases feedstock costs, (2) multiple enzymatic steps reduce overall flux, and (3) accumulation of the toxic by-product homolanthionine (formed via non-productive MetB side reactions) inhibits growth and methionine secretion 7,8,9.
Homolanthionine, a symmetrical disulfide-bridged amino acid, accumulates when MetB catalyzes the condensation of two O-acyl-homoserine molecules in the absence of sufficient cysteine 7,8,9. Concentrations exceeding 2-5 mM homolanthionine cause severe growth inhibition in Corynebacterium glutamicum 7. Rational metabolic engineering strategies to prevent homolanthionine accumulation include:
Strains with disrupted metB genes combined with overexpressed metE (cobalamin-independent methionine synthase) achieve L-Methionine titers of 45-60 g/L in fed-batch fermentation, representing 3-4 fold improvements over wild-type strains 7,9.
The terminal reaction in L-Methionine biosynthesis involves the methylation of L-homocysteine, catalyzed by two mechanistically distinct methionine synthases.
MetE (EC 2.1.1.13) utilizes 5-methyltetrahydrofolate (5-CH₃-THF) as the methyl donor in a zinc-dependent mechanism 10,14. The reaction proceeds via:
L-homocysteine + 5-CH₃-THF → L-Methionine + tetrahydrofolate 14
MetE exhibits KM values of 8-15 μM for L-homocysteine and 20-40 μM for 5-CH₃-THF in Corynebacterium species 10. The enzyme requires continuous regeneration of 5-CH₃-THF through the combined action of serine hydroxymethyltransferase (GlyA, EC 2.1.2.1) and 5,10-methylenetetrahydrofolate reductase (MetF, EC 1.5.1.20) 14. Overexpression of metF increases 5-CH₃-THF pools and enhances methionine synthesis rates by 25-35% in engineered Escherichia coli strains 14.
MetH (EC 2.1.1.14) employs methylcobalamin (vitamin B₁₂) as a prosthetic group and catalyzes the same net reaction as MetE but with superior kinetic parameters: kcat of 5-8 s⁻¹ versus 0.3-0.6 s⁻¹ for MetE 10,14. However, MetH requires exogenous cobalamin supplementation (typically 10-50 μg/L in fermentation media), increasing production costs 10. Most industrial L-Methionine production strains rely on MetE due to its cobalamin independence, though dual expression of both enzymes provides metabolic robustness under varying nutrient conditions 7,10.
The methionine biosynthetic pathway is subject to sophisticated transcriptional control mediated by dedicated repressor proteins that sense intracellular methionine and SAM concentrations.
In Corynebacterium glutamicum, the master regulator McbR (also designated MetD) controls expression of virtually all methionine biosynthetic genes (metA, metB, metC, metE, metF, metH, metK) as well as genes involved in sulfur assimilation and cysteine metabolism 7,8,9,10. McbR binds to conserved palindromic sequences in the promoter regions of target genes, repressing transcription in the presence of S-adenosyl-L-methionine (SAM), which serves as the co-repressor 7,10.
Deletion or attenuation of the mcbR gene results in constitutive derepression of methionine biosynthetic genes, leading to 5-10 fold increases in transcript levels and corresponding enhancements in L-Methionine production 7,8,9. However, uncontrolled derepression can cause metabolic imbalances, including:
Optimal industrial strains employ partial mcbR attenuation through promoter engineering or ribosome binding site modifications, achieving 2-3 fold transcriptional upregulation while maintaining metabolic homeostasis 8,9.
Escherichia coli utilizes the MetJ repressor, which binds to met boxes in the promoters of metA, metB, metC, metE, metF, and metH genes 14. Unlike McbR, MetJ uses S-adenosyl-L-methionine as a co-repressor but exhibits different DNA-binding specificity and regulatory logic 14. Deletion of metJ in E. coli increases methionine biosynthetic gene expression by 3-8 fold but also causes growth defects due to excessive methionine catabolism through SAM-dependent methyltransferases 14.
S-adenosyl-L-methionine represents the primary metabolic fate of L-Methionine in most organisms, serving as the universal methyl donor for >200 methyltransferase reactions and as a precursor for polyamines, ethylene (in plants), and various secondary metabolites 4,5.
SAM is synthesized from L-Methionine and ATP by S-adenosylmethionine synthetase (MetK, EC 2.5.1.6) in a reaction that consumes all three phosphate bonds of ATP 4,5:
L-Methionine + ATP → SAM + PPi + Pi
In Saccharomyces cerevisiae, the SAM1 and SAM2 genes encode functionally redundant SAM synthetases, and their combined overexpression increases intracellular SAM concentrations from ~50 μM to 200-300 μM 2. However, excessive SAM accumulation triggers feedback inhibition of methionine biosynthesis and activates SAM-dependent methyltransferases, creating futile cycles that deplete methionine pools 4,5.
SAM serves as the methyl donor for DNA methyltransferases, histone methyltransferases, protein arginine methyltransferases, and small molecule methyltransferases involved in neurotransmitter synthesis 4,5. Following methyl transfer, SAM is converted to S-adenosylhomocysteine (SAH), which is subsequently hydrolyzed by SAH hydrolase (EC 3.3.1.1) to yield L-homocysteine and adenosine 2,4,5.
Dysregulation of SAM metabolism is implicated in numerous pathological conditions 4,5:
Therapeutic SAM supplementation (typical doses: 400-1600 mg/day) has demonstrated efficacy in treating depression, osteoarthritis, and liver disease, though bioavailability remains a challenge due to first-pass metabolism 4,5.
Modern industrial L-Methionine production employs sophisticated metabolic engineering
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| ARKEMA FRANCE | Industrial biosynthesis of pharmaceutical-grade L-methionine for feed additives, medical raw materials, and nutraceutical applications requiring chiral purity. | Enzymatic L-Methionine Production System | Enzymatic conversion of L-methionine precursors with DMDS and organic reducing compounds, producing only L-enantiomer without D/L racemic mixture formation, eliminating petrochemical dependency. |
| ADISSEO FRANCE S.A.S. | Cost-effective industrial L-methionine fermentation with simplified downstream purification, avoiding organic acid accumulation and cytoplasmic acidification issues. | OPHS-Dependent Methionine Synthesis Platform | Utilizes O-phospho-L-homoserine pathway with mutated cystathionine gamma-synthase, eliminating acetate/succinate by-products, kcat values 0.8-3.5 s⁻¹, KM 0.5-2.0 mM for OPHS. |
| BASF SE | Large-scale microbial fermentation for animal feed and pharmaceutical L-methionine production, eliminating toxic by-product inhibition in Corynebacterium glutamicum systems. | Homolanthionine-Free Methionine Production Strain | McbR gene attenuation and MetB disruption prevents homolanthionine accumulation, achieving 45-60 g/L L-methionine titers with 3-4 fold improvement over wild-type strains. |
| Evonik Operations GmbH | Sustainable pharmaceutical and food-grade L-methionine production with improved energy efficiency and elimination of hazardous hydrogen cyanide chemistry. | Methional-Based Biocatalytic L-Methionine Synthesis | HCN-free biocatalytic conversion of methional to L-methionine, reducing energy requirements from 1 ATP + 2 NADPH + 2 ATP + 1 GTP + 4 NADPH to only 1 ATP + 2 NADPH. |
| MEDIQUEST THERAPEUTICS INC. | Clinical diagnostics and therapeutic interventions for cardiovascular disease, liver disorders, depression, and cognitive decline associated with SAM/SAH ratio dysregulation. | SAM Pathway Diagnostic and Therapeutic Platform | Modulation of S-adenosyl-L-methionine metabolic pathways for disease diagnosis and treatment, targeting methylation-dependent disorders including hyperhomocysteinemia, hepatic steatosis, and neurological conditions. |